MA33138B1 - Derives de benzothiazines, leur preparation et leur application a titre de medicaments - Google Patents

Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Info

Publication number
MA33138B1
MA33138B1 MA34191A MA34191A MA33138B1 MA 33138 B1 MA33138 B1 MA 33138B1 MA 34191 A MA34191 A MA 34191A MA 34191 A MA34191 A MA 34191A MA 33138 B1 MA33138 B1 MA 33138B1
Authority
MA
Morocco
Prior art keywords
representing
group
benzotiaziazine
drugs
derivatives prepared
Prior art date
Application number
MA34191A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Michel Perez
Marie Lamothe
Didier Junquero
Yves Rival
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA33138B1 publication Critical patent/MA33138B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
MA34191A 2009-03-03 2010-03-02 Derives de benzothiazines, leur preparation et leur application a titre de medicaments MA33138B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0951336A FR2942797B1 (fr) 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments
PCT/EP2010/052609 WO2010100139A1 (en) 2009-03-03 2010-03-02 Derivatives of benzothiazines, preparation thereof and application thereof as drugs

Publications (1)

Publication Number Publication Date
MA33138B1 true MA33138B1 (fr) 2012-03-01

Family

ID=40790339

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34191A MA33138B1 (fr) 2009-03-03 2010-03-02 Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Country Status (29)

Country Link
US (1) US9187438B2 (ru)
EP (1) EP2403840B1 (ru)
JP (1) JP5650139B2 (ru)
KR (1) KR101701531B1 (ru)
CN (1) CN102341379B (ru)
AR (1) AR075777A1 (ru)
AU (1) AU2010220335B2 (ru)
BR (1) BRPI1010243A2 (ru)
CA (1) CA2753630C (ru)
CL (1) CL2011002171A1 (ru)
CO (1) CO6501175A2 (ru)
ES (1) ES2483516T3 (ru)
FR (1) FR2942797B1 (ru)
GE (1) GEP20135832B (ru)
HK (1) HK1165802A1 (ru)
IL (1) IL214907A (ru)
MA (1) MA33138B1 (ru)
MX (1) MX2011008942A (ru)
MY (1) MY160819A (ru)
NZ (1) NZ595276A (ru)
PL (1) PL2403840T3 (ru)
RU (1) RU2523791C2 (ru)
SA (1) SA110310181B1 (ru)
SG (1) SG174208A1 (ru)
TN (1) TN2011000429A1 (ru)
TW (1) TWI495636B (ru)
UA (1) UA105040C2 (ru)
WO (1) WO2010100139A1 (ru)
ZA (1) ZA201107104B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
CN103271923B (zh) * 2013-06-28 2014-11-26 安徽中医学院 一种苯并噻嗪衍生物的医药用途
CN103304513B (zh) * 2013-06-28 2015-02-04 安徽中医学院 一类1,2-苯并噻嗪类化合物、制备方法及其应用
CN103275035B (zh) * 2013-06-28 2014-11-26 安徽中医学院 苯并噻嗪类化合物、其制备方法及其抗肿瘤用途
FR3035326B1 (fr) * 2015-04-21 2017-05-12 Pf Medicament Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
CN106243046B (zh) * 2016-08-02 2019-07-05 南京工业大学 一种甲基二磺隆的制备方法
US20200115353A1 (en) 2017-04-06 2020-04-16 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
WO2023154412A1 (en) * 2022-02-12 2023-08-17 Miralogx Llc Anti-inflammatory compounds, pharmaceutical compositions, and treatment methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
US3808205A (en) * 1971-09-10 1974-04-30 Warner Lambert Co Process for the preparation of 4-hydroxy-3-carbamyl-2h-1,2-benzothiazine 1,1-dioxides and 4-hydroxy-3(2h)-1,2-benzothiazine carboxylate-1,1-dioxides
US4289879A (en) * 1980-09-29 1981-09-15 Pfizer Inc. Synthetic method and intermediate for piroxicam
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
AU2002212672A1 (en) * 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
GB0224830D0 (en) * 2002-10-24 2002-12-04 Sterix Ltd Compound
DE602004025220D1 (de) * 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
CN103724335A (zh) * 2005-10-20 2014-04-16 默沙东公司 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物
RU2443689C2 (ru) * 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体

Also Published As

Publication number Publication date
SA110310181B1 (ar) 2013-08-27
NZ595276A (en) 2013-06-28
TW201035064A (en) 2010-10-01
JP2012519203A (ja) 2012-08-23
TN2011000429A1 (en) 2013-03-27
GEP20135832B (en) 2013-05-27
CL2011002171A1 (es) 2012-04-13
CN102341379B (zh) 2015-08-26
BRPI1010243A2 (pt) 2016-03-22
FR2942797A1 (fr) 2010-09-10
EP2403840B1 (en) 2014-05-14
CA2753630C (en) 2017-05-30
RU2011139014A (ru) 2013-04-10
AR075777A1 (es) 2011-04-27
US9187438B2 (en) 2015-11-17
IL214907A0 (en) 2011-11-30
TWI495636B (zh) 2015-08-11
FR2942797B1 (fr) 2011-04-29
KR101701531B1 (ko) 2017-02-01
CO6501175A2 (es) 2012-08-15
CN102341379A (zh) 2012-02-01
WO2010100139A1 (en) 2010-09-10
AU2010220335A1 (en) 2011-10-13
ZA201107104B (en) 2012-05-30
RU2523791C2 (ru) 2014-07-27
US20110319326A1 (en) 2011-12-29
SG174208A1 (en) 2011-10-28
IL214907A (en) 2015-02-26
HK1165802A1 (en) 2012-10-12
ES2483516T3 (es) 2014-08-06
MY160819A (en) 2017-03-31
PL2403840T3 (pl) 2014-10-31
KR20110122758A (ko) 2011-11-10
AU2010220335B2 (en) 2014-05-29
EP2403840A1 (en) 2012-01-11
MX2011008942A (es) 2011-09-27
JP5650139B2 (ja) 2015-01-07
CA2753630A1 (en) 2010-09-10
UA105040C2 (ru) 2014-04-10

Similar Documents

Publication Publication Date Title
MA33138B1 (fr) Derives de benzothiazines, leur preparation et leur application a titre de medicaments
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA29649B1 (fr) Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
MA32391B1 (fr) Activateurs de la glucokinase
MA33761B1 (fr) Dispersion solide de rifaximine
MX2008013728A (es) Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo.
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
MA31953B1 (fr) Nouveaux derives du thiophene.
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
WO2005074897A3 (de) Formulierungshilfsmittel (aminopropansäure derivative) in kosmetischen oder dermatologischen zubereitungen
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA30082B1 (fr) Derives de pyrimidine
TW200716635A (en) Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TNSN08196A1 (fr) Derives de pyrazine
BRPI0810719A8 (pt) Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
MX2009004343A (es) Compuestos organicos.
TW200714297A (en) Hair and/or scalp care compositions incorporating flavonoid compounds
TN2010000173A1 (fr) Antagonistes de cgrp
MA33320B1 (fr) Derives de rifamycine
RS50229B (sr) Analozi vitamina d3